Am J Addict. 2006 Jan-Feb;15(1):100-4.  Links
Study of the efficacy of fluoxetine and clomipramine in the treatment of premature ejaculation after opioid detoxification.
Ibn E Sina Hospital of Psychiatry, Mashhad University of Medical Sciences, Mashhad, Iran.
Premature ejaculation is a common symptom that can provoke relapse in formerly opioid-dependent men after detoxification. The purpose of this study was to compare the efficacy of clomipramine and fluoxetine for the treatment of premature ejaculation in formerly opioid-dependent men after detoxification. Sixty opium-detoxified men with A & B DSM-IV diagnostic criteria for premature ejaculation participated in a prospective two-week descriptive inferential clinical trial after a two-week washout period. The subjects did not consume any other medications but naltrexone for maintenance of an opium-free state. The subjects were randomly divided into two groups of thirty subjects, one group received fluoxetine (10 mg/d for the first and 20 mg/d for the second week), and the other received clomipramine (25 mg/d for the first and 50 mg/d for the second week). Twenty five subjects did not continue the treatment and were lost to follow-up. The severity of the premature ejaculation was graded regarding the subjects' report in weeks 0, 1, and 2. Mann Whitney-U and Wilcoxon non-parametric tests were used for statistical analysis. Fluoxetine (10 mg/d then 20 mg/d) and clomipramine (25 mg/d then 50 mg/d) were both effective in the treatment of premature ejaculation and did not show any difference in efficacy. The severity of premature ejaculation did not show any relation to the subjects' age, education level, opioid type, or route of abuse. Fluoxetine and clomipramine both can be equally used in the treatment of premature ejaculation following opioid detoxification, depending on their side effects and other symptoms in the subjects.
 
 
Psychol Rep. 2004 Aug;95(1):192-6. Links
Persistent neuropsychological problems after 7 years of abstinence from recreational Ecstasy (MDMA): a case study.
Department of Psychology, School of Psychology, University of East London, UK. k.soar@uel.ac.uk
This case study concerns a 26-yr.-old male who had consumed large amounts of Ecstasy seven years previously. He stated that his increasingly intensive use of ecstasy over a 4-yr. period had led to the emergence of multiple psychiatric and psychological problems. Given these problems, he stopped using Ecstasy, but the problems had not resolved despite seven years of abstinence. The neurocognitive profile was very similar to that shown by current heavy Ecstasy users, with deficits in immediate and delayed verbal recall, moderately impaired memory function, but normal expressive language ability and perceptual functioning. Extremely high pathology was evident, including depression and phobic anxiety. Severe problems with sleep and sex were also reported. Further studies involving larger groups of abstinent former users are needed; adverse sequelae associated with intensive Ecstasy use may sometimes be enduring.
 

 


Informativa sull'utilizzo dei cookie.
Questo sito utilizza cookie tecnici, di terze parti e di profilazione (propri e di altri siti) per migliorare la tua esperienza di navigazione. Se vuoi saperne di pił o negare il consenso a tutti o ad alcuni cookie clicca qui.
Se clicchi su OK oppure chiudi questo banner, acconsenti all'uso dei cookie. Ti ricordiamo che la mancata accettazione dei cookie tecnici potrebbero impedire alcune funzionalitą di questo sito.